Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009

Houston, Keisha A.; Henley, S. Jane; Li, Jun; White, Mary C.; Richards, Thomas B.

doi:10.1016/j.lungcan.2014.08.001

Cited by 181 publications

(150 citation statements)

References 44 publications

(43 reference statements)

Supporting

Mentioning

126

Contrasting

Unclassified

Order By: Relevance

“…The latter two reports highlighted that, although ihc staining might not always be required for nsclc subtyping, it clearly lowers the rate of nsclc nos diagnoses. The results reported by VanderMeer et al 17 are consistent with those from other academic centres and suggest the use of ihc in their cohort, compared with the larger provincial study in which more than 40% of cases were signed out without a pathologic subtype 4 .…”

supporting

confidence: 82%

“…Of those diagnosed, approximately 85% have non-small-cell lung cancer (nsclc). In that subgroup, approximately 40% have adenocarcinoma histology; 10%-15%, squamous cell carcinoma; and 5%-10%, neuroendocrine carcinoma; the rest are classified as not otherwise specified (nos) [2][3][4] . Recent developments in the therapy and understanding of the pathobiology of lung cancer have triggered a refinement of the histologic classifications to take into account the advent of novel targeted therapies and chemotherapy agents 5 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Ready or Not? Lung Cancer Diagnosis in 2015

2015

View full text Add to dashboard Cite

Lung cancer remains a significant health issue in Canada, with more than 26,000 new cases reported in 2014 1 . The disease also unfortunately remains the cause of the greatest number of cancer-related deaths, at more than 20,000 annually. That toll is attributed in part to half of all patients presenting upfront with metastatic disease. Of those diagnosed, approximately 85% have non-small-cell lung cancer (nsclc). In that subgroup, approximately 40% have adenocarcinoma histology; 10%-15%, squamous cell carcinoma; and 5%-10%, neuroendocrine carcinoma; the rest are classified as not otherwise specified (nos) 2-4 . Recent developments in the therapy and understanding of the pathobiology of lung cancer have triggered a refinement of the histologic classifications to take into account the advent of novel targeted therapies and chemotherapy agents 5 . Most importantly, the new classifications have been based on a multidisciplinary collaborative effort that has included clinicians, pathologists, radiologists, and molecular biologists-underscoring the exciting revolution underway in the field of lung cancer management.Although platinum doublets have been standard in the therapy of advanced nsclc across all histologies, more recent studies have demonstrated the importance of histology in determining optimal therapy 6 . Pemetrexed has demonstrated the differential effect of histology on treatment response, with survival benefit restricted to those with adenocarcinoma histology 7,8 . Conversely, regimens incorporating bevacizumab have been associated with significant toxicity in patients with squamous histology, leading to the development and use of that agent in nonsquamous nsclc 9,10 .The discovery of molecular biomarkers such as EGFR gene mutations and ALK gene rearrangements have triggered the era of targeted therapy in lung cancer. Those molecular targets are both strongly associated with adenocarcinoma histology and are highly predictive of response to tyrosine kinase inhibitors, with better outcomes than are seen with conventional chemotherapy 11-13 . The pivotal i-pass study, which compared gefitinib with conventional chemotherapy in never-or light-smoking Asian patients with metastatic adenocarcinoma, served to highlight the importance of ascertaining the molecular status of patients before initiating therapy 11 . Patients with activating mutations experience better response, better quality of life, and better progression-free (and likely even overall) survival with initial targeted therapy. By contrast, those with wild-type EGFR or ALK adenocarcinoma experience better outcomes with initial chemotherapy.

show abstract

supporting

confidence: 82%

mentioning

confidence: 99%

Ready or Not? Lung Cancer Diagnosis in 2015

2015

View full text Add to dashboard Cite

show abstract

“…Globocan 2012 reported an estimated 1.8 million new lung cancer cases in 2012 (12.9% of the total) and 1.59 million deaths, accounting for almost one in five cancer deaths (19.4% of the total) in the world. In most Western countries, lung cancer incidence and mortality rates have been decreasing; in the United States (US), lung cancer incidence significantly decreased among men, although it remained stable among women during 2004–2009 1. In contrast, lung cancer incidence and mortality rates are still increasing in China 1, 2, 3…”

Section: Introductionmentioning

confidence: 99%

Lung cancer burden has increased during the last 40 years in Hebei Province, China

Song

et al. 2016

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundIn 2011, Hebei Province, located in North China with a population of 71 794 239, accounted for approximately 6% of the national population. It is well known as a heavily air polluted area. This study reports the lung cancer burden and mortality trend in Hebei Province from 1973 to 2011.MethodsEight cancer registries in Hebei Province submitted data to the Hebei Provincial Cancer Registry Center. Pooled data were stratified by area (urban/rural), gender, and age group. The proportions, cumulative incidence/mortality rates, and median age at death of lung cancer were calculated. Lung cancer mortality data of 1973–1975, 1990–1992, and 2004–2005 were extracted from national death surveys. Data of lung cancer from Cixian and Shexian were obtained from population‐based cancer registries in each county.ResultsThe estimated numbers of newly diagnosed lung cancer cases and deaths in 2011 in Hebei Province were 32 623 and 27 612, respectively. The crude incidence rate of lung cancer was 45.44/100 000. The age‐standardized incidence rate by world standard population was 39.01/100 000, ranking second among all cancers. The lung cancer mortality rate was 38.46/100 000, ranking first among all cancer deaths, with a significantly increasing trend in Hebei Province from 1973–1975 to 2010–2011, with an increased rate of 189.15%.Conclusion Hebei Province suffers a heavy disease burden of lung cancer and an obvious increasing trend has been observed over the past 40 years. Preventive and control strategies should be encouraged.

show abstract

“…Indeed, a Japanese study showed the usefulness of AFI for detection of latent airway ischemic damage in pigs that had undergone tracheal autotransplantation, allowing early treatment of the anastomotic site and preventing stricture formation (20). Lastly, AFB may be a recommended procedure in addition with WLB for follow-up in patients with known severe dysplasia or CIS in the central airway (21), helping to guide surgical resection range when necessary, and reducing postoperative recurrence rate.…”

Section: A B Cmentioning

confidence: 99%

The role of bronchoscopy in the diagnosis of early lung cancer: a review

Andolfi¹,

Potenza²,

Capozzi³

et al. 2016

J. Thorac. Dis.

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths worldwide with an overall 5-year survival rate of 17% after diagnoses. Indeed many patients tend to have a very poor prognosis, due to being diagnosed at an advanced stage. Conversely patients who are diagnosed at an early stage have a 5-year survival >70%, indicating that early detection of lung cancer is crucial to improve survival. Although flexible bronchoscopy is a relatively non-invasive procedure for patients suspected of having lung cancer, only 29% of carcinoma in situ (CIS) and 69% of microinvasive tumors were detectable using white light bronchoscopy (WLB) alone. As a result, in the past two decades, new bronchoscopic techniques have been developed to increase the yield and diagnostic accuracy, such as autofluorescence bronchoscopy (AFB), narrow band imaging (NBI) and high magnification bronchovideoscopy (HMB). However, due to the low specificity and the limitation to detect only proximal bronchial tree, new probe-based technologies have been introduced: radial endobronchial ultrasound (R-EBUS), optical coherence tomography (OCT), confocal laser endomicroscopy (CLE) and laser Raman spectroscopy (LRS). To date, although tissue biopsy remains the gold standard for diagnosing malignant/premalignant airway disease and some techniques are still investigational, bronchoscopic technologies can be considered the safest and most accurate tools to evaluate both central and distal airway mucosa.

show abstract

Patterns in lung cancer incidence rates and trends by histologic type in the United States, 2004–2009

Cited by 181 publications

References 44 publications

Ready or Not? Lung Cancer Diagnosis in 2015

Ready or Not? Lung Cancer Diagnosis in 2015

Lung cancer burden has increased during the last 40 years in Hebei Province, China

The role of bronchoscopy in the diagnosis of early lung cancer: a review

Contact Info

Product

Resources

About